메뉴 건너뛰기




Volumn 25, Issue 5, 2010, Pages 1604-1608

Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients

Author keywords

Aluminium overload; DFO; Dialysis; Haemodialysis; Low dose DFO

Indexed keywords

ALKALINE PHOSPHATASE; ALUMINUM; CALCIUM; DEFEROXAMINE; FERRITIN; PARATHYROID HORMONE; PHOSPHATE;

EID: 77951692952     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp649     Document Type: Article
Times cited : (20)

References (21)
  • 1
    • 22844441609 scopus 로고    scopus 로고
    • Frequency of elevated serum aluminum levels in adult dialysis patients
    • DOI 10.1053/j.ajkd.2005.04.020, PII S0272638605005664
    • Jaffe JA, Liftman C, Glickman JD. Frequency of elevated serum aluminium levels in adult dialysis patients. Am J Kidney Dis 2005; 46: 316-319 (Pubitemid 41040361)
    • (2005) American Journal of Kidney Diseases , vol.46 , Issue.2 , pp. 316-319
    • Jaffe, J.A.1    Liftman, C.2    Glickman, J.D.3
  • 2
    • 0027403453 scopus 로고
    • Diagnostic and therapeutic approaches to aluminium overload in dialysed patients - Representative study by questionnaire in West German dialysis units in 1989-1990
    • Humpfner A, Hummel S, Schultz W. Diagnosis and therapeutic approaches to aluminium overload in dialysed patients-representative study questionnaire in West German Dialysis units in 1989-1990. Nephrol Dial Transplant 1993; 8: S51-S54 (Pubitemid 23115854)
    • (1993) Nephrology Dialysis Transplantation , vol.8 , Issue.SUPPL. 1 , pp. 51-54
    • Humpfner, A.1    Hummel, S.2    Schulz, W.3
  • 3
    • 33751564527 scopus 로고    scopus 로고
    • A new era in phosphate binder therapy: What are the options?
    • Salusky IB. A new era in phosphate binder therapy: what are the options? Kidney Int 2006; 105: S10-S15
    • (2006) Kidney Int , vol.105
    • Salusky, I.B.1
  • 4
    • 0141432172 scopus 로고    scopus 로고
    • NKF-K/DOQI. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease
    • NKF-K/DOQI. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S108-S122
    • (2003) Am J Kidney Dis , vol.42
  • 5
    • 77951683663 scopus 로고    scopus 로고
    • Henrich WLAluminium toxicity in end-stage renal disease
    • BD Rose (ed) Waltham, MA: UpToDate
    • Cronin RE, Henrich WLAluminium toxicity in end-stage renal disease. In: BD Rose (ed). UpToDate. Waltham, MA: UpToDate, 2006
    • (2006) UpToDate
    • Cronin, R.E.1
  • 6
    • 0024505752 scopus 로고
    • Exacerbation of aluminium encephalopathy after treatment with desferrioxamine
    • McCauley J, Sorkin MI. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant 1989; 4: 110-114 (Pubitemid 19077599)
    • (1989) Nephrology Dialysis Transplantation , vol.4 , Issue.2 , pp. 110-114
    • McCauley, J.1    Sorkin, M.I.2
  • 8
    • 0026318477 scopus 로고
    • Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry
    • Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18: 660-667
    • (1991) Am J Kidney Dis , vol.18 , pp. 660-667
    • Boelaert, J.R.1    Fenves, A.Z.2    Coburn, J.W.3
  • 9
    • 0024587762 scopus 로고
    • Irreversible ocular toxicity from single 'challenge' dose of deferoxamine
    • Bene C, Manzler A, Bene D, et al. Irreversible ocular toxicity from single "challenge" dose of deferoxamine. Clin Nephrol 1989; 31: 45-48 (Pubitemid 19033536)
    • (1989) Clinical Nephrology , vol.31 , Issue.1 , pp. 45-48
    • Bene, C.1    Manzler, A.2    Bene, D.3    Kranias, G.4
  • 10
    • 0023240050 scopus 로고
    • Ocular toxicity after a single intravenous dose of desferrioxamine in 2 hemodialyzed patients
    • Pengloan J, Dantal J, Rossazza C, et al. Ocular toxicity after a single intravenous dose of desferrioxamine in 2 hemodialyzed patients. Nephron 1987; 46: 211-212 (Pubitemid 17074323)
    • (1987) Nephron , vol.46 , Issue.2 , pp. 211-212
    • Pengloan, J.1    Dantal, J.2    Rossazza, C.3
  • 11
    • 0023877556 scopus 로고
    • Acute visual and auditory neuro-toxicity in patients with end-stage renal disease receiving desferrioxamine
    • Cases A, Kelly J, Sabater J, et al. Acute visual and auditory neuro-toxicity in patients with end-stage renal disease receiving desferrioxamine. Clin Nephrol 1988; 29: 176-178
    • (1988) Clin Nephrol , vol.29 , pp. 176-178
    • Cases, A.1    Kelly, J.2    Sabater, J.3
  • 12
    • 0030045385 scopus 로고    scopus 로고
    • Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules
    • Barata JD, D'Haese PC, Pires C, et al. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant 1996; 11: 125-132 (Pubitemid 26038477)
    • (1996) Nephrology Dialysis Transplantation , vol.11 , Issue.1 , pp. 125-132
    • Barata, J.D.1    D'Haese, P.C.2    Pires, C.3    Lamberts, L.V.4    Simoes, J.5    De Broe, M.E.6
  • 13
    • 0028849828 scopus 로고
    • Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload
    • D'Haese PC, Couttenye MM, Goodman WG, et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 1995; 10: 1874-1884
    • (1995) Nephrol Dial Transplant , vol.10 , pp. 1874-1884
    • D'Haese, P.C.1    Couttenye, M.M.2    Goodman, W.G.3
  • 14
    • 0029907095 scopus 로고    scopus 로고
    • Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients
    • DOI 10.1007/BF00820731
    • Janssen MJ, van Boven WP. Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients. Pharm World Sci 1996; 18: 187-191 (Pubitemid 26364528)
    • (1996) Pharmacy World and Science , vol.18 , Issue.5 , pp. 187-191
    • Janssen, M.J.A.1    Van Boven, W.P.L.2
  • 17
    • 0022844293 scopus 로고
    • Diagnosis of aluminium-related bone disease and treatment of aluminium toxicity with deferoxamine
    • Jack W, Norris KC. Diagnosis of aluminium-related bone disease and treatment of aluminium toxicity with deferoxamine. SeminNephrol 1986; 6: 12-21
    • (1986) SeminNephrol , vol.6 , pp. 12-21
    • Jack, W.1    Norris, K.C.2
  • 18
    • 1342335772 scopus 로고
    • Effect of aluminum on parathyroid hormone secretion
    • Morrissey J, Slatopolsky E. Effect of aluminium on parathyroid hormone secretion. Kidney Int 1986; 18: S41-S44 (Pubitemid 16114644)
    • (1986) Kidney International , vol.28 , Issue.SUPPL. 18
    • Morrissey, J.1    Slatopolsky, E.2
  • 19
    • 0025228544 scopus 로고
    • Hyperparathyroidism after aluminium depletion
    • Almirall J, Campistol JM, Torras A, et al. Hyperparathyroidism after aluminium depletion. Nephron 1990; 55: 94-95
    • (1990) Nephron , vol.55 , pp. 94-95
    • Almirall, J.1    Campistol, J.M.2    Torras, A.3
  • 20
    • 63849210667 scopus 로고    scopus 로고
    • Chemistry and history of phosphate binder
    • Koiwa F, Sato Y. Chemistry and history of phosphate binder. Clin Calcium 2009; 19: 198-204
    • (2009) Clin Calcium , vol.19 , pp. 198-204
    • Koiwa, F.1    Sato, Y.2
  • 21
    • 65349156550 scopus 로고    scopus 로고
    • Role of medication in the level of aluminium in the blood of chronic renal patients
    • Bohrer D, Bertagnolli DC, de Oliveira SM, et al. Role of medication in the level of aluminium in the blood of chronic renal patients. Nephrol Dial Transplant 2009; 24: 1277-1281
    • (2009) Nephrol Dial Transplant , vol.24 , pp. 1277-1281
    • Bohrer, D.1    Bertagnolli, D.C.2    De Oliveira, S.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.